(6) Based on what is known about the behavior of the antibody and
the available pharmacokinetic data, Prothena CEO Gene Kinney has stated (albeit without presenting modeling to support the assertion) that «we would expect to fully saturate that pathological load [of aggregated AS] in patients with Parkinson's disease.»